Empagliflozin Ameliorates Bleomycin-Induced Pulmonary Fibrosis in Rats by Modulating Sesn2/AMPK/Nrf2 Signaling and Targeting Ferroptosis and Autophagy.
Empagliflozin透過調節Sesn2/AMPK/Nrf2訊號,並針對ferroptosis和自噬,改善大鼠博莱霉素誘導的肺纖維化。
Int J Mol Sci 2023-06-12
Reversal of fibrosis and portal hypertension by Empagliflozin treatment of CCl<sub>4</sub>-induced liver fibrosis: Emphasis on gal-1/NRP-1/TGF-β and gal-1/NRP-1/VEGFR2 pathways.
Empagliflozin治療CCl<sub>4</sub>誘導的肝纖維化可逆轉纖維化和門脈高壓:重點放在gal-1/NRP-1/TGF-β和gal-1/NRP-1/VEGFR2途徑。
Eur J Pharmacol 2023-11-12
Empagliflozin and liraglutide ameliorate HFpEF in mice via augmenting the Erbb4 signaling pathway.
Empagliflozin和liraglutide透過增強Erbb4信號通路改善小鼠的HFpEF。
Acta Pharmacol Sin 2024-04-08
Canagliflozin alleviates pulmonary hypertension by activating PPARγ and inhibiting its S225 phosphorylation.
Canagliflozin透過激活PPARγ並抑制其S225磷酸化來緩解肺動脈高壓。
Acta Pharmacol Sin 2024-05-08
Empagliflozin attenuates epithelial to mesenchymal transition through senescence in peritoneal dialysis.
Empagliflozin透過衰老在腹膜透析中減緩上皮向間質轉變。
Am J Physiol Renal Physiol 2024-07-04
Empagliflozin prevents heart failure through inhibition of the NHE1-NO pathway, independent of SGLT2.
Empagliflozin 透過抑制 NHE1-NO 通路來預防心衰竭,與 SGLT2 無關。
Basic Res Cardiol 2024-07-24
Empagliflozin improves aortic injury in obese mice by regulating fatty acid metabolism.
Empagliflozin 透過調節脂肪酸代謝改善肥胖小鼠的主動脈損傷。
Open Med (Wars) 2024-08-23